Hu Zhang.

Almost every resveratrol supplement on the market is a Polygonum cuspidatum extract rather than a grape extract, because the root concentration is orders of magnitude higher. Polydatin (resveratrol-3-glucoside) is present alongside the free aglycone and is hydrolysed to resveratrol by intestinal and bacterial glucosidases. Anyone taking both a resveratrol product and this root is likely taking the same material twice under two names. Check the label before stacking.

Resveratrol is cleared extremely fast by sulfation and glucuronidation in the gut wall and liver, which is why oral bioavailability of the free compound is so low. Quercetin inhibits those same enzymes and competes for them as a substrate. The documented result in pharmacokinetic work is higher unconjugated resveratrol when the two are given together. That is an exposure change, not a demonstrated clinical benefit.

Resveratrol is glucuronidated so efficiently in the enterocyte that most of an oral dose never reaches circulation as the free compound. Piperine slows that step and raises plasma exposure. The same inhibition applies to medicines cleared by glucuronidation, so this is not a free lunch. Anyone on prescription medicine should raise it with a prescriber.

The glucoside form needs bacterial beta-glucosidase to release the aglycone, and gut bacteria then convert a large share of resveratrol to dihydroresveratrol. That means the metabolite profile a person ends up with depends on their microbiome, not just on the dose swallowed. It is one reason interindividual variation in resveratrol studies is so wide. Whether a specific probiotic strain shifts this usefully is unestablished.

Trans-resveratrol dissolves poorly in water and needs bile salts and dietary fat to form the mixed micelles that carry it to the enterocyte. Taking the extract with a fat-containing meal or a lipid-based format raises uptake compared with a dry capsule on an empty stomach. This is formulation physics rather than a pharmacological interaction. The size of the effect varies with the format used.

Pterostilbene is resveratrol with two methoxy groups replacing hydroxyls, which removes two sites for sulfation and gives it substantially longer plasma persistence. The two are often stacked on the reasoning that they cover the same ground at different exposure profiles. They also compete for some of the same clearance enzymes. No trial has tested the combination against either alone.

NR raises NAD availability as a precursor, while resveratrol has been proposed to act on sirtuin activity, a proposal that has been actively contested in the literature since the original assay work was challenged. Products routinely combine them on the strength of that shared story. The mechanistic case is genuinely unsettled and should be presented as such. No combination trial supports the pairing.

Resveratrol inhibits platelet aggregation in vitro and the root also contains emodin, an anthraquinone with its own effects. EPA shifts prostanoid production toward less aggregatory species. Two mild effects on one endpoint deserve a flag for anyone on anticoagulant or antiplatelet medicine, or before surgery. This is mechanistic caution rather than a documented clinical bleeding signal.

Silymarin components inhibit UGT1A1 and several CYPs, and resveratrol acts on overlapping conjugation enzymes. Together they raise the chance of altering plasma levels of co-administered medicines. This is not a synergy anyone should be buying for. It belongs on the record as an interaction flag.

Emodin and related anthraquinones in Polygonum cuspidatum stimulate colonic motility, which is why crude root preparations can loosen stools in a way that purified resveratrol does not. Adding a bulk-forming fibre changes stool form on top of that. Loose stools from a resveratrol product usually point to a crude extract with a meaningful anthraquinone fraction. Purified or decolourised extracts largely remove that issue.

Poorly absorbed magnesium salts draw water into the bowel, and crude Hu Zhang extract contributes anthraquinone-driven motility. The two together produce more urgency than either alone. Switching to magnesium glycinate or to a low-anthraquinone extract removes the overlap. This is dose management, not a reason to avoid either.